Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma

Zhuo-yi Liu, Song-shan Feng, Yi-hao Zhang, Li-yang Zhang, Sheng-chao Xu, Jing Li, Hui Cao, Jun Huang, Fan Fan, Li Cheng, Jun-yi Jiang, Quan Cheng & Zhi-xiong Liu

The prognostic factors and optimal treatment for the elderly patient with glioblastoma (GBM) were poorly understood. This study extracted 4975 elderly patients (≥ 65 years old) with histologically confirmed GBM from Surveillance, Epidemiology and End Results (SEER) database. Firstly, Cumulative incidence function and cox proportional model were utilized to illustrate the interference of non-GBM related mortality in our cohort. Then, the Fine-Gray competing risk model was applied to determine the prognostic factors for GBM related mortality. Age ≥ 75 years old, white race, size > 5.4 cm, frontal lobe tumor, and overlapping lesion were independently associated with more GBM related death, while Gross total resection (GTR) (HR 0.87, 95%CI 0.80–0.94, \( P = 0.010 \)), radiotherapy (HR 0.64, 95%CI 0.55–0.74, \( P < 0.001 \)), chemotherapy (HR 0.72, 95%CI 0.59–0.90, \( P = 0.003 \)), and chemoRT (HR 0.43, 95%CI 0.38–0.48, \( P < 0.001 \)) were identified as independently protective factors of GBM related death. Based on this, a corresponding nomogram was conducted to predict 3-, 6- and 12-month GBM related mortality, the C-index of which were 0.763, 0.718, and 0.694 respectively. The calibration curve showed that there was a good consistency between the predicted and the actual mortality probability. Concerning treatment options, GTR followed by chemoRT is suggested as optimal treatment. Radiotherapy and chemotherapy alone also provide moderate clinical benefits.

Glioblastoma (GBM) are the most common malignant tumor in central nerves system (CNS) with dismal prognosis. The incidence of GBM is increasing with advancing age and it is reported that more than half of the patients with GBM were older than 65 years old. Also, older age is a validated predictor for poor clinical outcome for patients with GBM. However, the prognostic factors and optimal therapeutic strategy of elderly (age ≥ 65) with GBM are still controversial. Several meta-analysis studies of the elderly with GBM suggested that maximal surgical resection and postoperative ChemoRT provided promising clinical benefits for the elderly with GBM. But there is still no large-scale retrospective study to validate the conclusions extracted from small-scale single-center clinical studies. Also elderly patients who died from non-GBM related causes such as cardiovascular disease and stroke will result in non-negligible competing risk bias. But as far as I am concerned, all existed studies focused...
on elderly patients with GBM didn’t take this into consideration. Therefore, the current comprehension of the elderly with GBM is still insufficient and imprecise.

Cox proportional hazard model and Kaplan–Meier survival curve are the conventional analytic methods to determine the prognostic factors, while cumulative incidence function (CIF) curve and Fine-Gray competing risk model are more suitable for elderly patients, which can eliminate the interference of competing risk bias9. We took advantage of Surveillance, Epidemiology and End Results (SEER) database to include 4975 elderly patients with histologically confirmed GBM, which provided a detailed record of causes of death. This is the first large-scale population-based study based on competing risk model to determine prognostic factors and optimal therapeutic options for this frail patient group.

Method

Study population. The National Cancer Institute sponsored SEER database was searched to identify the elderly with histologically confirmed GBM between 2007 and 2016. The SEER database provides de-identified information including cancer incidence, patients' demographic, tumor characteristics, treatment options, and survival outcomes. All patients with histologically confirmed GBM were firstly included. Then, patients with age < 65 years old were excluded. Patients with unknown tumor characteristics, demographic information, and survival status were excluded. Concerning radiotherapy, only the patients treated with beam radiation after surgery or no/unknown were included. Regarding surgical resection, the patients treated with no surgery (code 00) were excluded. The final study population strictly included patients treated with biopsy (code 20), subtotal resection (STR, code 21), or gross total resection (GTR, codes 30, 40, and 55) (Fig. 1).

Covariates included. The following patient data was obtained for the analysis: age group (< 75 years old, ≥ 75 years old), sex (female, male), race (other, white, and black), marital status (single, married/partner, unmarried/divorced, and widowed), insurance status (privately insured, Medicaid, and uninsured), size (size ≤ 5.4 cm, size > 5.4 cm, the best cut-off value was defined according to X-tile software), metastasis (yes, no), primary site (temporal, cerebrum, frontal, parietal, occipital, ventricle, cerebellum, brainstem, and overlapping lesion). Concerning treatment options, extent of surgery (biopsy, STR GTR) and adjuvant therapy (radiotherapy, chemotherapy, ChemoRT, no/unknown) were analyzed (Table 1).

Statistical analyses. The baseline patient characteristics were compared among patients treated with different extent of surgery by Chi-square test. GBM related death and non-GBM related death were defined as two competing events. Firstly, Cumulative incidence function (CIF) was plotted to show the probability of GBM related mortality (curve1) and non-GBM related mortality (curve2), Gray's test was applied to analyze the differences between groups. Secondly, the univariate and multivariable Cox proportional regression were used to reveal the relationship between the covariates and non-GBM related mortality. Thirdly, univariate and multivariable competing risk analyses were utilized to identify prognostic factors for GBM related mortality to eliminate the interference of competing events8,10. Finally, a corresponding nomogram based on the identified prognostic
factors were then conducted to predict 3-month, 6-month, and 12-month GBM related mortality using the R packages rms and mstage. The discrimination performance of the nomogram was evaluated by concordance index (C-index) and a calibration curve was plotted via a bootstrap method with 1000 resamples to estimate the consistency between the predicted and the actual survival probability. All statistical analyses were performed in R version 3.5.1. R packages cmprsk were used for the competing risk analysis, rms and mstage were utilized to build the model and nomogram. pec was applied to evaluate the performance of the nomogram. P < 0.05 was considered statistically significant.

Results

Characteristics of the study population. 4975 patients were included. The median survival month of the cohort was 8 months. The 3-month, 6-month, and 12-month overall survival rates were 75.6%, 56.9%, and 34.2% respectively. 2558 patients (51.4%) received GTR, 1226 (24.5%) patients got STR, and 1191 patients (23.9%) treated with biopsy only. The OS rates of biopsy, STR, and GTR group were 7.9%, 16.6%, and 14.1%.

| Characteristics      | All | Biopsy (%) | GTR (%) | STR (%) | P value |
|----------------------|-----|------------|---------|---------|---------|
| Population size      | 4975 | 1191 (23.9) | 2558 (51.4) | 1226 (24.5) | |
| Age group            |      |            |         |         | <0.001 |
| <75                  | 3285 | 741 (22.6) | 1753 (53.4) | 791 (24.0) | |
| ≥75                  | 1690 | 450 (26.6) | 805 (47.6) | 435 (25.8) | |
| Sex                  |      |            |         |         | 0.143   |
| Female               | 2202 | 542 (24.2) | 1171 (52.5) | 523 (23.3) | |
| Male                 | 2733 | 649 (23.8) | 1381 (50.5) | 703 (25.7) | |
| Race                 |      |            |         |         | 0.003   |
| Black                | 207  | 65 (31.4)  | 103 (49.8) | 39 (18.8)  | |
| Other                | 231  | 53 (22.9)  | 103 (44.6) | 75 (32.5)  | |
| White                | 4537 | 1073 (23.7)| 2352 (51.8) | 1112 (24.5)| |
| Marital status       |      |            |         |         | 0.007   |
| Divorced/separated   | 410  | 108 (26.3) | 204 (49.8) | 98 (23.9)  | |
| Married/partner      | 3343 | 745 (22.3) | 1754 (52.5) | 844 (25.2) | |
| Single               | 414  | 117 (28.3) | 192 (46.4) | 105 (25.4) | |
| Widowed              | 808  | 221 (27.4) | 408 (50.5) | 179 (22.1) | |
| Insurance            |      |            |         |         | 0.047   |
| Privately insured    | 4600 | 1096 (23.8)| 2370 (51.5) | 1134 (24.7)| |
| Medicaid             | 348  | 85 (24.4)  | 182 (52.3) | 81 (23.3)  | |
| Uninsured            | 27   | 10 (37.0)  | 6 (22.2)  | 11 (40.7)  | |
| Primary site         |      |            |         |         | <0.001  |
| Temporal             | 1595 | 321 (20.1) | 883 (55.4) | 391 (24.5) | |
| Cerebrum             | 70   | 47 (67.1)  | 8 (11.4)  | 15 (21.5)  | |
| Frontal              | 1406 | 329 (23.4) | 728 (51.8) | 349 (24.8) | |
| Parietal             | 899  | 232 (25.8)| 457 (50.8) | 210 (23.4) | |
| Occipital            | 273  | 57 (20.9)  | 156 (57.1) | 60 (22.0)  | |
| Ventricle            | 10   | 4 (40.0)   | 4 (40.0)  | 2 (20.0)   | |
| Cerebellum           | 29   | 8 (27.6)   | 16 (55.2) | 5 (17.2)   | |
| Brainstem            | 1    | 1 (100)    | 0 (0.0)   | 0 (0.0)    | |
| Overlapping          | 692  | 192 (27.8)| 306 (44.2) | 194 (28.0) | |
| Size                 |      |            |         |         | <0.001  |
| > 5.4 cm             | 1337 | 300 (21.8)| 6661 (48.4)| 411 (29.8)| |
| ≤ 5.4 cm             | 3598 | 891 (24.8)| 1892 (52.6)| 815 (22.7)| |
| Metastasis           |      |            |         |         | 0.014   |
| No                   | 4928 | 1178 (23.9)| 2543 (51.6)| 1207 (24.5)| |
| Yes                  | 47   | 13 (27.7)  | 15 (31.9) | 19 (40.3)  | |
| Adjuvant therapy     |      |            |         |         | <0.001  |
| No/unknown           | 861  | 241 (28.0)| 430 (49.9) | 190 (22.1) | |
| Radiotherapy         | 530  | 153 (28.9)| 252 (47.5)| 125 (23.6) | |
| Chemotherapy         | 142  | 36 (25.4)  | 79 (55.6) | 27 (19.0)  | |
| ChemoRT              | 3442 | 761 (22.1)| 1797 (52.1)| 884 (25.7) | |

Table 1. Patient demographics, tumor characteristics and treatment options of 4975 elderly with glioblastoma. GTR gross total resection, STR subtotal resection. *P < 0.05, statistically significant.
respectively. Most preoperative covariates, except sex ($P=0.143$) were statistically different among groups of biopsy, STR, and GTR. More patients in $<75$ years old group received GTR than $\geq 75$ years old group. (53.4% vs. 47.6%, $P<0.001$). Patients with white race and patients grouped as married/partner had relatively higher GTR rate (51.8% and 52.5%, respectively). Patients with tumor size $\leq 5.4$ cm had a significantly higher GTR rate (52.6% vs. 48.4%, $P<0.001$). Concerning tumor site, more than 50% of tumors located in occipital lobe, temporal lobe, cerebellum, frontal lobe, and parietal lobe received GTR. (57.1%, 55.4%, 55.2%, 51.8%, and 50.8% respectively), while cerebrum and overlapping tumor had relatively lower GTR rates. (44.2% and 11.4% respectively). For brainstem and ventricular tumor, the population size is too small to get accurate data. (n = 1 and n = 10, respectively) (Table 1).

Interferences of non-GBM related death. At the time of data collected, 13.2% ($n=659$) of patients were alive, and 82.1% ($n=4082$) of patients died from GBM, and 4.7% ($n=234$) of patients died from competing causes. The result of CIF showed that patients in $\geq 75$ years old, black race, divorced, Medicare, with metastasis, biopsy, and no/unknown adjuvant therapy groups had significantly higher risk of death from non-GBM related death (Fig. 2). The results of univariate and multivariable cox analysis showed that $<75$ years old, female, married, medicaid, GTR (HR 0.90, 95%CI 0.84–0.95, $P<0.001$), Radiotherapy (HR 0.65, 95%CI 0.58–0.72, $P<0.001$), chemotherapy (HR 0.61, 95%CI 0.53–0.70, $P<0.001$), and chemoRT (HR 0.46, 95%CI 0.43–0.50, $P<0.001$) had an independently significant association with less non-GBM related death (Table 2).

Prognostic factors of GBM related death. CIF revealed that patients in $\geq 75$ years old, white race, size $>5.4$ cm, and overlapping lesion groups had significantly higher probability of GBM related death, while married/partner, GTR, and chemoRT were significantly associated with less GBM related death (Fig. 2). Further univariate and multivariable competing risk analyses were conducted to identify independent prognostic factors for GBM related death. The result showed that $\geq 75$ years old, white race, frontal lobe tumor, overlapping tumor, brainstem tumor, size $>5.4$ cm were identified as independently risk factors of GBM related death. Regarding treatment options, GTR (HR 0.87, 95%CI 0.80–0.94, $P=0.010$), radiotherapy (HR 0.64, 95%CI 0.55–0.74, $P<0.001$), chemotherapy (HR 0.72, 95%CI 0.59–0.90, $P=0.003$), and chemoRT (HR 0.43, 95%CI 0.38–0.48, $P<0.001$) were identified as independently protective factors for GBM related death. STR showed no significant relation with GBM related death in both univariate (HR 0.96, 95%CI 0.88–1.05, $P=0.35$) and multivariable (HR 1.03, 95%CI 0.93–1.13, $P=0.60$) competing risk analysis (Table 3).

Competing risk nomogram. Identified predictors including age group, sex, surgery, adjuvant, size, and site were integrated to develop the prognostic competing risk nomogram to predict the 3-month, 6-month, and 12-month GBM related mortality with C-index of 0.763, 0.718, and 0.694 respectively, which showed relative good discriminative. Site and adjuvant therapy were the top two strong predictors (Fig. 3). Calibration plots showed good agreement between the nomogram-predicted probabilities and actual observations (Fig. 4).

Discussion
When patients with GBMs died from causes e.g. infections, injury, accidents, cardiovascular or cerebrovascular events, these deaths are competing risks. This phenomenon was much more frequently observed in the elderly population. Analysis based on OS results in an upward bias in the estimate of incidence, while the cause-specific cox model will underestimate the incidence as it treats non-GBM related death as censored observations. In our study cohort, the median survival month is 8 months, and 4.7% ($n=234$) of patients died from competing causes. Although the percentage of non-GBM related death is not high, it caused non-negligible interference. The result of CIF and cox proportional analysis for non-GBM death showed that several covariates including extent of surgery and adjuvant therapy had a significant association with non-GBM related death. These results indicated that the Fine-Gray competing risk model was of great necessity to eliminate bias, especially for determining the prognostic value of GTR and adjuvant therapy in this study.

Concerning tumor characteristics, frontal lobe tumor, overlapping tumor, brainstem tumor, and size $>5.4$ cm were identified as independent risk factors of GBM related death smaller tumor size usually represented lower invasiveness and were more accessible to GTR. Patients with tumor size $\leq 5.4$ cm had a significantly higher GTR rate (52.6% vs. 48.4%, $P<0.001$) in our cohort. Frontal lobe tumor, brainstem tumor, and overlapping lesion tumor reported having worse prognosis due to its infiltrative nature or critical anatomical position. GTR was identified independently related to decreased risks of non-GBM related death, which indicated that patients who received GTR may have a relatively better general condition. At the same time, GTR was proved to provide significantly protective effects from GBM related death after eliminating the competing risk bias. Consistently, most studies reported that GTR was superior to biopsy only with regards to OS. However, there is still no consensus about the effects of STR. Our analyses revealed STR compared with biopsy had no
significant association with decreased risk of GBM related death in univariate and multivariate competing analyses. A meta-analysis searched studies before 2014 concluded that the STR compared with biopsy experienced a significantly better OS of 2.55 months (95% CI 0.91–4.19, \( P = 0.002 \))\(^{23}\). However, this study didn’t adjust the confound effects of other covariates by multivariate regression. Another retrospective study including 124 patients (≥ 65 years) with GBM also reported that STR significantly improved OS compared with biopsy (Median 11.0 and 4.0 months, \( P < 0.02 \)). However, the association between STR and improved OS was significant only in univariate analysis. Besides, a higher rate of complication was observed in STR compared with biopsy. (42.9% vs. 7.4%)\(^{21}\).

In a recent retrospective study including 273 patients (65–84 years) with GBM, multivariate analysis revealed the benefit of STR over biopsy was significant only in the 65–75 years group (\( P = 0.01 \)) but not the 75–84 years group (\( P = 0.081 \))\(^{12}\). According to our analysis and existed studies, GTR can provide valid clinical benefits for the elderly with GBM, which should be offered whenever safely possible. For patients couldn’t achieve GTR,
biopsy rather than STR was generally preferred. More subgroup analyses were needed to determine which part of patients would benefit from STR.

ChemoRT showed the greatest protective effect for GBM related death (HR 0.46, 95%CI 0.43–0.50, \(P < 0.001\)) in our analyses. Consistent with our results, a population-based study including 5252 elderly with GBM (> 70 years, RT: n = 1389; chemoRT: n = 3863) reported that chemoRT was significantly associated with better OS than RT (HR 0.79, 95% CI 0.70–0.89, \(P < 0.001\)) on multivariate analysis.24 Another retrospective study of 117 elderly with GBM reported the median OS months of patients who accessed chemoRT (n = 84) and those who didn’t (n = 33) were 11 and 5 months respectively. Another study including 616 patients with GBM from CGGA and TCGA databases also concluded that chemoRT could benefit both old and young patients, but old

**Table 2.** Univariate and multivariable cox proportional analyses for non-GBM related death in elderly patients with glioblastoma. GTR gross total resection, STR subtotal resection. \(^*P < 0.05, \) statistically significant;
patients are currently less likely to choose it\(^2\). In our cohort, the percentage of the patient received chemoRT was decreasing with advancing age (76.3% in < 75 years old group and 59.5% in ≥ 75 years old group), meaning older patients had significantly less tolerance to adjuvant therapy. Recently, several studies have suggested that hypofractionated RT combined with CT provide similar or even better survival benefit compared with standard RT combined with CT, which is more tolerable for older patients\(^5,6,25\). Our results also revealed that either RT (HR 0.64, 95%CI 0.55–1.51, \(P \text{ < 0.001}\)) or CT (HR 0.72, 95%CI 0.59–0.90, \(P = 0.003\)) also provide modest protective effect in GBM related death compared with no/unknown. Consistently, a clinical trial including 85 patients (≥ 70 years) with GBM reported that RT had a modest improvement in OS (HR 0.47, 95%CI 0.29–0.76, \(P = 0.002\))\(^26\). Another clinical trial enrolling 373 patients (≥ 65 years) with GBM reported that CT was considered

| **Table 3.** Univariate and multivariable competing risk analyses for GBM related death in elderly patients with glioblastoma. GTR gross total resection, STR subtotal resection. \(^*P < 0.05, \) statistically significant. |

| **Univariate analysis** | **Multivariable analysis** |
|------------------------|---------------------------|
| **HR (95%CI)**          | **HR (95%CI)**            |
| **P value**             | **P value**               |
| **Age**                 |                           |
| < 75                    | 1 [Reference]             | 1 [Reference]              |
| ≥ 75                    | 1.41 (1.32–1.51)          | < 0.001\(^*\)              |
|                         | 1.22 (1.14–1.32)          | < 0.001\(^*\)              |
| **Sex**                 |                           |
| Female                  | 1 [Reference]             | 1 [Reference]              |
| Male                    | 0.97 (0.92–1.03)          | 0.37                       |
|                         | 1.01 (0.94–1.08)          | 0.87                       |
| **Race**                |                           |
| Other                   | 1 [Reference]             | 1 [Reference]              |
| Black                   | 1.13 (0.92–1.39)          | 0.260                      |
|                         | 1.13 (0.89–1.42)          | 0.33                       |
| White                   | 1.27 (1.11–1.47)          | < 0.001\(^*\)              |
|                         | 1.33 (1.14–1.54)          | < 0.001\(^*\)              |
| **Marital status**      |                           |
| Single                  | 1 [Reference]             | 1 [Reference]              |
| Divorced/separated       | 0.91 (0.79–1.07)          | 0.280                      |
|                         | 0.95 (0.80–1.12)          | 0.51                       |
| Married/partner          | 0.86 (0.78–1.07)          | 0.016                      |
|                         | 0.93 (0.82–1.06)          | 0.26                       |
| Widowed                 | 1.17 (0.98–1.28)          | 0.110                      |
|                         | 1.07 (0.92–1.24)          | 0.41                       |
| **Insurance status**    |                           |
| Insured                 | 1.04 (0.91–1.18)          | 0.59                       |
|                         | 1.11 (0.96–1.29)          | 0.15                       |
| Uninsured               | 1.18 (0.71–2.00)          | 0.52                       |
|                         | 1.27 (0.82–1.98)          | 0.27                       |
| **Primary site**        |                           |
| Temporal                | 16.5 (14.8–18.5)          | < 0.001\(^*\)              |
|                         | 10.1 (8.54–11.9)          | < 0.001\(^*\)              |
| Brainstem               | 1.03 (0.69–1.47)          | 0.98                       |
|                         | 0.95 (0.56–1.61)          | 0.85                       |
| Cerebrum                | 1.28 (0.95–1.74)          | 0.11                       |
|                         | 1.14 (0.79–1.64)          | 0.48                       |
| Frontal                 | 1.17 (1.08–1.26)          | < 0.001\(^*\)              |
|                         | 1.17 (1.08–1.27)          | < 0.001\(^*\)              |
| Occipital               | 0.92 (0.80–1.05)          | 0.21                       |
|                         | 0.93 (0.81–1.08)          | 0.37                       |
| Overlapping             | 1.18 (1.17–1.30)          | 0.007\(^*\)                |
|                         | 1.18 (1.07–1.31)          | 0.002\(^*\)                |
| Parietal                | 1.05 (0.47–2.37)          | 0.90                       |
|                         | 1.05 (0.95–1.15)          | 0.34                       |
| Ventricle               | /                         | /                          |
|                         | 0.93 (0.45–1.93)          | 0.85                       |
| **Size**                |                           |
| ≤ 5.4                   | 1.23 (1.15–1.31)          | < 0.001\(^*\)              |
|                         | 1.19 (1.10–1.28)          | < 0.001\(^*\)              |
| > 5.4                   |                           |
| **Metastasis**          |                           |
| No                      | 1 [Reference]             | 1 [Reference]              |
| Yes                     | 1.07 (0.70–1.63)          | 0.75                       |
|                         | 0.91 (0.58–1.42)          | 0.68                       |
| **Surgery**             |                           |
| Biopsy                  | 0.82 (0.76–0.89)          | < 0.001\(^*\)              |
|                         | 0.87 (0.80–0.94)          | 0.010\(^*\)                |
| GTR                     | 0.96 (0.88–1.05)          | 0.35                       |
|                         | 1.03 (0.93–1.13)          | 0.60                       |
| STR                     |                           |
| **Adjuvant therapy**    |                           |
| No/unknown              | 1 [Reference]             | 1 [Reference]              |
| Both                    | 0.41 (0.36–0.46)          | < 0.001\(^*\)              |
|                         | 0.43 (0.38–0.48)          | < 0.001\(^*\)              |
| Chemotherapy            | 0.70 (0.56–0.86)          | < 0.001\(^*\)              |
|                         | 0.72 (0.59–0.90)          | 0.003\(^*\)                |
| Radiotherapy            | 0.63 (0.54–0.72)          | < 0.001\(^*\)              |
|                         | 0.64 (0.55–0.74)          | < 0.001\(^*\)              |
equally effective compared with RT (HR 1.09, 95% CI 0.84–1.42, \( P = 0.033 \))\(^ {27} \). Both our analyses and existed studies suggested chemoRT was the optimal treatment for elderly patients with GBM. When it is intolerable, RT or CT alone were an alternative to provide moderate clinical benefits. Elderly GBM patients should receive customized adjuvant therapy whenever feasible.

This study has several limitations. Despite SEER database contains abundant medical records, it lacks some important information including neurological performance and function grading, tumor recurrence and quality of life, molecular signature and genetic alteration, detailed RT dosage and CT regimen, and type of treatment center. This study also has its strengths. This is the first large-scale retrospective study based on competing risk model to analyze elderly patients with GBM, which provides information with less bias and more strengths. And we highlighted the clinical benefits of GTR and adjuvant therapy for elderly patients with GBM.

**Conclusion**

This study takes advantage of competing risk model to determine prognostic factors for the elderly patient with GBM accurately. Preoperative factors including \( \geq 75 \) years old, white race, frontal lobe tumor, overlapping tumor, brainstem tumor, size > 5.4 cm were identified as risk factors. The competing risk nomogram was discriminative.
GTR followed by chemoRT is suggested as optimal treatment. RT or CT alone also provides moderate clinical benefits. Elderly patients with GBM should receive customized adjuvant therapy whenever feasible.

Received: 25 October 2020; Accepted: 12 April 2021
Published online: 29 April 2021

References
1. Ostrom, Q. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 21, v1–v100 (2019).
2. Li, G. et al. Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. Cancer Med. 9(6), 1935–1965 (2020).
3. Xia, Y. et al. Nomograms for predicting the overall and cancer-specific survival of patients with high-grade glioma: a surveillance, epidemiology, and end results study. Turk. Neurosurg. 30(1), 48–59 (2020).
4. Han, Q., Liang, H., Cheng, P., Yang, H. & Zhao, P. Gross total vs. subtotal resection on survival outcomes in elderly patients with high-grade glioma: a systematic review and meta-analysis. Front. Oncol. 10, 151 (2020).
5. Nassiri, F. et al. Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: a systematic review and network meta-analysis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26(11), 2664–2672 (2020).
6. Kalra, B., Kannan, S. & Gupta, T. Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis. J. Neuro-oncol. 146(2), 311–320 (2020).
7. van Walraven, C. & Hawken, S. Competing risk bias in Kaplan–Meier risk estimates can be corrected. J. Clin. Epidemiol. 70, 101–105 (2016).
8. Scrucca, L., Santucci, A. & Aversa, F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl. 45(9), 1388–1395 (2010).
9. Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94(446), 496–509 (1999).
10. Scrucca, L., Santucci, A. & Aversa, F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl. 40(4), 381–387 (2007).
11. Zhang, Z., Geskus, R. B., Kattan, M. W., Zhang, H. & Liu, T. Nomogram for survival analysis in the presence of competing risks. Ann. Transl. Med. 5(20), 403 (2017).
12. Ahmadipour, Y. et al. To resect or not to resect? Risks and benefits of surgery in older patients with glioblastoma. J. Geriatr. Oncol. 11(4), 688–693 (2020).
13. Ostrom, Q., Cote, D., Ascha, M., Kruchko, C. & Barnholtz-Sloan, J. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 4(9), 1254–1262 (2018).
14. Xie, J., Yang, S., Liu, X. & Zhao, Y. Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status. Cancer Med. 7(8), 3722–3742 (2018).
15. Liu, S., Liu, X., Xiao, Y., Chen, S. & Zhuang, W. Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. PLoS ONE 14(1), e0211513 (2019).
16. Edwards, B. & Clarke, V. The psychological impact of a cancer diagnosis on families: the influence of family functioning and patients’ illness characteristics on depression and anxiety. Psychooncology 13(8), 562–576 (2004).
17. Tian, M. et al. Impact of gender on the survival of patients with glioblastoma. Biosci. Rep. 38(6), 1–9 (2018).
18. Yang, Y. et al. Prognostic nomograms for primary high-grade glioma patients in adult: a retrospective study based on the SEER database. BioMed. Res. Int. 2020, 1346340 (2020).
19. Puglisi, G. et al. Preserving executive functions in nondominant frontal lobe glioma surgery: an intraoperative tool. J. Neurosurg. 131(2), 474–480 (2018).
20. Liang, J. et al. Prognostic factors of patients with gliomas—an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer 20(1), 35 (2020).
21. Hoffermann, M. et al. Treatment results and outcome in elderly patients with glioblastoma multiforme—a retrospective single institution analysis. Clin. Neurol. Neurosurg. 128, 60–69 (2015).
22. Zhang, C. et al. Analysis of treatment tolerance and factors associated with overall survival in elderly patients with glioblastoma. World Neurosurg. 95, 77–84 (2016).
23. Almenawer, S. A. et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol. 17(6), 868–881 (2015).
24. Huang, J. et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J. Neuro-oncol. 131(3), 593–601 (2017).
25. Perry, J. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376(11), 1027–1037 (2017).
26. Keime-Guibert, F. et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356(15), 1527–1535 (2007).
27. Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13(7), 707–715 (2012).

Author contributions
Zx.L., S.F., and Y.Z. made substantial contributions to the design of this study. Zy.L. and Q.C. carried out the analysis and interpreted the data. Y.Z., S.X., and L.Z. made contributions to the drafting of the manuscript. J.L., H.C., and J.J made contributions to the review of previous literature. J.H., F.F. and L.C. contributed substantially to the revision of the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (NO. 82073893, NO. 81703622, NO. 81472693, and NO. 81873635), China Postdoctoral Science Foundation (NO. 2018M633002), Hunan Provincial Natural Science Foundation of China (NO. 2018JJ3838, NO. 2018SK2101, and No. 2020JJ8111), Hunan provincial health and Health Committee Foundation of China (C2019186).

Competing interests
The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Q.C. or Z.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021